Overview and Scope
Urinary incontinence is a medical condition characterized by the unintentional loss of urine, ranging from occasional leaks to a complete inability to control urination. Weakened pelvic floor muscles, hormonal changes, obesity, neurological conditions, urinary tract infections, medications and pregnancy can cause urinary incontinence.
Sizing and Forecast
The urinary incontinence market size has grown strongly in recent years. It will grow from $11.61 billion in 2023 to $12.52 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to aging population, awareness of urinary incontinence, rising prevalence of urinary incontinence, increasing access to healthcare, rising disposable incomes.
The urinary incontinence market size is expected to see strong growth in the next few years. It will grow to $16.19 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to increasing prevalence of comorbidities, lifestyle factors, population health strategies, growing healthcare expenditures. Major trends in the forecast period include medical advancements, innovative technologies, non-invasive treatments, digital health and mhealth, innovative product designs, patient-centered care.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/urinary-incontinence-global-market-report
Segmentation & Regional Insights
The urinary incontinence market covered in this report is segmented –
1) By Type: Urge Incontinence; Stress Incontinence; Overflow Incontinence; Functional Incontinence
2) By Treatment Type: Medication; Devices; Other Treatments
3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administrations
4) By Diagnosis: Physical Exam; Pad Test; Urodynamic Testing; Cystoscopy; Stress Test; Ultrasound; Urine Samples
5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
North America was the largest region in the urinary incontinence market in 2023. The regions covered in urinary incontinence market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12946&type=smp
Major Driver Impacting Market Growth
The increase in the prevalence of urological disorders is expected to propel the growth of the urinary incontinence market going forward. Urological disorders, also known as urologic conditions, refer to a wide range of medical conditions that affect the urinary system and the male reproductive organs, including the kidneys, bladder, ureters, urethra and male reproductive organs such as the prostate and testes. The increasing prevalence of urological disorders, particularly conditions like urinary incontinence, fuels the demand for products and treatments to address these issues. Further improving awareness and diagnosis, innovations in medicine and healthcare infrastructure. For instance, in January 2023, according to the report published by the American Cancer Society Inc., a US-based voluntary organization for cancer awareness, the estimated cases of urinary bladder cancer increased to 82,290 in 2023, an increase of 1.1% from 81,400 in 2020 in the United States. Therefore, the increase in the prevalence of urological disorders will drive the growth of the urinary incontinence market.
Key Industry Players
Major players in the urinary incontinence market are Cardinal Health Inc., Johnson and Johnson, Medtronic PLC, Eli Lilly and Company, Asahi Kasei Corporation, Becton Dickinson and Company (C.R. Bard Inc.), Teva Pharmaceutical Industries Ltd., Berry Global Inc., Boston Scientific Corporation, Mylan N.V., Sun Pharmaceutical Industries Ltd., Domtar Corporation, Cook Medical Inc., Aurobindo Pharma Ltd., Coloplast AIS, Teleflex Incorporated, Apotex Inc., Zydus Lifesciences Limited, ConvaTec Group PLC, Cook Group Inc., Torrent Pharmaceuticals Ltd., Alennbic Pharmaceuticals Limited, Laborie Medical Technologies Corp., NeoTract Inc., Ethicon Inc., Promedon GmbH, Caldera Medical Inc.
The urinary incontinence market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
Explore the trending research reports from TBRC:
Urinary Incontinence & Pelvic Organ Prolapse Devices And Equipment Global Market Report 2024
Urinary Drainage Bags Global Market Report 2024
Nephrology And Urology Devices Global Market Report 2024
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Have you been experiencing those leaky moments quite often lately?
And it gets worse when you sneeze, laugh, or cough!
You might want to look out for more information on urinary incontinence now.
Prolonged urinary leakage can be a sign of urinary incontinence in many cases.
The global Urinary Incontinence Treatment Drugs Market research report, published by Value Market Research, is designed to offer various market framework such as market size, portion, trends, growth path, value and factors that impact the current market dynamics over the forecast period 2020-2027.
Most importantly, this report also provides the latest significant strategies adopted by major players along with their market share.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the urinary incontinence treatment drugs market include Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Sanofi S.A.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Urinary Incontinence Treatment Drugs Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/urinary-incontinence-treatment-drugs-market/download-sampleMarket DynamicsUrinary incontinence is one of the most prevalent medical conditions seen in the elderly population.
One-third of females older than 65 years are known to cause urinary incontinence treatment, and 12 % have daily incontinence.
Growing approvals by FDA for new drugs and growing research to develop new medicines is stimulating growth.
